BioStock: Aqilion’s CEO: “We estimate a peak sales potential of a blockbuster magnitude”

Swedish biotech company Aqilion continues to make strides in the field of chronic inflammatory diseases. The company is now preparing for the next phase of clinical development for AQ280, a selective JAK1 inhibitor, in eosinophilic esophagitis. To support these efforts, Aqilion is conducting a rights issue of approximately SEK 26.8 million, with the subscription period running until March 12. BioStock spoke with CEO Sarah Fredriksson to learn more about the plans going forward.
– In the AQ280 base case scenario, we estimate a peak sales potential in an order of a blockbuster magnitude”, says CEO Sarah Fredriksson.

Read the interview at biostock.se:

https://www.biostock.se/en/2025/03/aqilions-ceo-we-estimate-a-peak-sales-potential-of-a-blockbuster-magnitude/

This is a press release from BioStock - Connecting Innovation and Capital. https://www.biostock.se/en/